Minerva Neurosciences | NERV - ДОЛГ





ДОЛГ Изменить Дата
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Adma Biologics USD 83.12M 702K 2025-09
ALKERMES USD 71.6M 1.08M 2025-09
Alterity Therapeutics Limited AUD 210.39K 120.67K 2023-06
AstraZeneca USD 32.63B 207M 2025-09
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Cipla INR 4.38B 231.9M 2025-03
Clal Biotechnology ILS 35.76M 28.27M 2023-12
Compugen USD 2.95M 24K 2025-09
CSL USD 11.96B 219M 2024-12
Eli Lilly USD 42.51B 2.6B 2025-09
Esperion Therapeutics USD 262.92M 1.76M 2024-09
GlaxoSmithKline GBP 17.75B 396M 2025-09
Grifols EUR 9.23B 626.05M 2024-12
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
J&J USD 45.8B 4.97B 2025-09
Merck USD 41.37B 5.97B 2025-09
Minerva Neurosciences USD 0 0 2024-09
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Novartis USD 32.64B 1.37B 2025-06
Novavax USD 233.31M 4.23M 2024-09
Pfizer USD 60.85B 78M 2025-09
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 21.76B 530M 2025-09
Takeda JPY 4.85T 208B 2025-12
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12